Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer

Free Subscription 13.04.2026 1 ACS Appl Mater Interfaces 1 Adv Sci (Weinh) 1 Ann Med Surg (Lond) 4 Arch Esp Urol 1 Biochem Biophys Res Commun 2 bioRxiv 3 BJU Int 2 BMJ Case Rep 1 Br J Cancer 1 Cell Commun Signal 2 Cell Death Dis 1 Clin Chim Acta 2 Clin Genitourin Cancer 1 Commun Biol 1 Cytopathology 1 Eur Radiol 4 Eur Urol 2 Front Immunol 1 Histopathology 1 Insights Imaging 1 Int J Biol Sci 1 Int J Gen Med 1 Int J Genomics 1 Int J Urol 1 Int Urol Nephrol 1 J Urol 1 Lab Med 1 Mol Cell Biochem 1 Nano Lett 1 Nat Commun 1 Nat Rev Urol 1 Oncogene 1 Oncol Rep 1 Oncology 2 Photodiagnosis Photodyn Ther 1 Proc Natl Acad Sci U S A 1 Sci Rep 4 Urol Oncol 1 Urology 1 Virchows Arch 1 Zhonghua Bing Li Xue Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

ACS Appl Mater Interfaces

1. ZENG S, Xing S, Yu X, Liu X, et al
   In-Situ Self-Assembling Multifunctional Peptide-Hydrogel Enables Efficient Bladder Cancer Therapy via Sustained Release of Bacillus Calmette-Guerin and Enhanced Immune Response.
   ACS Appl Mater Interfaces. 2026 Apr 5. doi: 10.1021/acsami.6c01301.
   PubMed         Abstract available
   
   

   
   Adv Sci (Weinh)

2. GUO B, Xu C, Fu S, Cheng Q, et al
   NQO1-Mediated Anoikis Resistance and Immune Evasion Define a High-Risk Multi-Omic Subtype for Precision Management of T1 High-Grade Bladder Cancer.
   Adv Sci (Weinh). 2026 Apr 7:e23605. doi: 10.1002/advs.202523605.
   PubMed         Abstract available
   
   

   
   Ann Med Surg (Lond)

3. ANJUM A, Siddiqui MJ, Ali AMN, Ahmed J, et al
   Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis.
   Ann Med Surg (Lond). 2026;88:2661-2668.
   PubMed         Abstract available
   
   

   
   Arch Esp Urol

4. VALENCIA NIETO P, Lopez-Campos F, Diezhandino Garcia P, Duque-Santana V, et al
   Adjuvant Radiotherapy After Cystectomy in Muscle-Invasive Bladder Cancer: Indications, Benefits and Remaining Challenges.
   Arch Esp Urol. 2026;79:160-168.
   PubMed         Abstract available
   
   
5. CHERNOBILSKY V, Gonzalez IT, Favre G
   Efficacy and Safety of Keyhole Limpet Hemocyanin in Bacillus Calmette-Guerin Unresponsive Non-muscle Invasive Bladder Cancer.
   Arch Esp Urol. 2026;79:219-223.
   PubMed         Abstract available
   
   
6. KAYAR K, Verim L, Sonmez D, Kadihasanoglu M, et al
   Distribution of PD-1.5 Gene Variant (rs2227981): A Possible Approach for Risk Assessment in Bladder Cancer.
   Arch Esp Urol. 2026;79:233-240.
   PubMed         Abstract available
   
   
7. ZHENG K, Cui X, Liu Y, Du M, et al
   Risk Factors and Predictive Model for Peripherally Inserted Central Catheter Tip Migration in Patients With Bladder Cancer.
   Arch Esp Urol. 2026;79:352-361.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

8. HUANG H, Guo L, Sun H, Liu Y, et al
   Saikosaponin D inhibits bladder cancer growth and enhances the synergistic antitumor effect of gemcitabine by targeting PI3K/AKT-mediated ferroptosis.
   Biochem Biophys Res Commun. 2026;816:153709.
   PubMed         Abstract available
   
   

   
   bioRxiv

9. OLUMOYIN KD, Aydin AM, Bazargan S, Bunch B, et al
   PETIL: Predicting Expansion of Tumor Infiltrating Lymphocytes for the Adoptive Cell Immunotherapy in Bladder Cancers.
   bioRxiv [Preprint]. 2026 Mar 13:2025.10.15.682695.
   PubMed         Abstract available
   
   
10. ANDERSON HG, Bazargan S, Nusbaum DJ, Poch MA, et al
    A virtual cohort framework with applications to adoptive cell therapy in bladder cancer.
    bioRxiv [Preprint]. 2026 Mar 10:2026.03.06.710135.
    PubMed         Abstract available
    
    

    
    BJU Int

11. FU MZ, Packiam VT, Byrne J
    Response to comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.
    BJU Int. 2026 Apr 8. doi: 10.1111/bju.70271.
    PubMed        
    
    
12. KUMAR V, Kant R
    Comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.
    BJU Int. 2026 Apr 6. doi: 10.1111/bju.70268.
    PubMed        
    
    
13. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
    Digital Uromonitor(R) outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Manageme
    BJU Int. 2026 Apr 6. doi: 10.1111/bju.70230.
    PubMed         Abstract available
    
    

    
    BMJ Case Rep

14. SAHOO B, Nayak MK, Ygl K, Aribaskar S, et al
    Bleeding ileal conduit varices in a postoperative patient of urinary bladder carcinoma: percutaneous transhepatic variceal embolization to the rescue.
    BMJ Case Rep. 2026;19:e266103.
    PubMed         Abstract available
    
    
15. LEITE TFO, Parreira D, Nunes TF
    Superselective vesical artery embolisation in the management of haemorrhagic radiation cystitis.
    BMJ Case Rep. 2026;19:e270850.
    PubMed         Abstract available
    
    

    
    Br J Cancer

16. XING Z, Xu H, Lin P, Hong Y, et al
    ITGB4 up-regulated by STAT3 reduces the sensitivity of bladder cancer to cisplatin by suppressing p53.
    Br J Cancer. 2026 Apr 9. doi: 10.1038/s41416-026-03364.
    PubMed         Abstract available
    
    

    
    Cell Commun Signal

17. LOURENCO C, Constancio V, Tavares NT, Monteiro-Reis S, et al
    From cell lines to the clinic: identifying a urinary BlCa-EV signature through comparative proteomics of bladder cancer lysates and extracellular vesicles.
    Cell Commun Signal. 2026 Apr 9. doi: 10.1186/s12964-026-02868.
    PubMed         Abstract available
    
    

    
    Cell Death Dis

18. LIU S, Liu X, Liu G, Wang Z, et al
    Nuclear hexokinase 2 couples hyperglycemia to MYC-driven glycolytic and stemness programs in bladder cancer.
    Cell Death Dis. 2026 Apr 8. doi: 10.1038/s41419-026-08714.
    PubMed         Abstract available
    
    
19. CHENG Y, Chen T, Zheng G, Song Z, et al
    PSMD11 stabilizes PGM3 by antagonizing Parkin to promote bladder cancer progression through energy metabolism reprogramming.
    Cell Death Dis. 2026 Apr 6. doi: 10.1038/s41419-026-08691.
    PubMed         Abstract available
    
    

    
    Clin Chim Acta

20. ALRAMADNEH TN, Mutee AF, Kubaev A, Qayumova S, et al
    Circulating biomarkers in bladder cancer: emerging evidence and future directions for personalized therapy.
    Clin Chim Acta. 2026;588:120992.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

21. MOUW KW, Shin KY, Parisi J, Zhai B, et al
    Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026;24:102548.
    PubMed         Abstract available
    
    
22. MUSHTAQ A, Zabor EC, Adcock B, Dhakal A, et al
    Real-World Survival Outcomes and Prognostic Factors in De Novo Stage IV Urothelial Bladder Cancer: A 13-Year Retrospective Cohort Study.
    Clin Genitourin Cancer. 2026 Mar 16:102541. doi: 10.1016/j.clgc.2026.102541.
    PubMed         Abstract available
    
    

    
    Commun Biol

23. ZHAO M, Wang X, Duan X, Wu C, et al
    Ferroptosis as a therapeutic vulnerability in ARID1A-deficient bladder cancer.
    Commun Biol. 2026 Apr 10. doi: 10.1038/s42003-026-09998.
    PubMed         Abstract available
    
    

    
    Cytopathology

24. DEY P, Muralidaran C
    Comparative Evaluation of Transfer Learning Models for Detecting Malignant Cells in Urinary Cytology.
    Cytopathology. 2026;37:232-239.
    PubMed         Abstract available
    
    

    
    Eur Radiol

25. FAN Z, Li D, Chen W, Li Y, et al
    Application of transformer-enhanced convolutional neural network: multicenter MRI assessment of muscle invasion in bladder cancer.
    Eur Radiol. 2026 Apr 4. doi: 10.1007/s00330-026-12497.
    PubMed         Abstract available
    
    

    
    Eur Urol

26. COLD KM, Vasquez JL
    Re: Jethro C.C. Kwong, Zizo Al-Daqqaq, Yashan Chelliahpillai, et al. Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression R
    Eur Urol. 2026 Apr 7:S0302-2838(26)02064-6. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
27. ZHOU J, Liu P
    Re: Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial.
    Eur Urol. 2026 Apr 2:S0302-2838(26)02051-8. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
28. LI D
    Re: Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).
    Eur Urol. 2026 Apr 2:S0302-2838(26)02045-2. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
29. ZHOU Q, Ma H
    Re: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
    Eur Urol. 2026 Apr 8:S0302-2838(26)02047-6. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Front Immunol

30. YANG G, Wang Y, Fan Z, Wei G, et al
    Rapid establishment of KRAS-driven bladder cancer initiation and immune escape models using genetically engineered mice and organoid approaches.
    Front Immunol. 2026;17:1726443.
    PubMed         Abstract available
    
    
31. DAI Y, Xiao C, Wang L, Zhou W, et al
    Efficacy and safety of antibody-drug conjugate based therapy in locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis of emerging clinical evidence.
    Front Immunol. 2026;17:1728521.
    PubMed         Abstract available
    
    

    
    Histopathology

32. JHA S, Lobo A, Sangoi AR, Kandukuri SR, et al
    Molecular characterization of clear cell adenocarcinoma of the urinary bladder.
    Histopathology. 2026;88:1167-1183.
    PubMed         Abstract available
    
    

    
    Insights Imaging

33. SUN M, Wang J, Luo J, Lai S, et al
    Assessment of multi-parameter dual-energy CT in predicting muscle invasion in bladder cancer: comparison with VI-RADS.
    Insights Imaging. 2026;17:96.
    PubMed         Abstract available
    
    

    
    Int J Biol Sci

34. LIU Y, Shi ZD, Wei YF, Jiang SY, et al
    Apigenin Suppresses Bladder Cancer via the SIRT6-NCOA2-PPARalpha Axis.
    Int J Biol Sci. 2026;22:3070-3086.
    PubMed         Abstract available
    
    

    
    Int J Gen Med

35. LI W, Xiang C, Xie G, Zhang Y, et al
    Postoperative Neutrophil-to-Albumin Ratio as a Prognostic Marker for Patients with Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Observational Cohort Study.
    Int J Gen Med. 2026;19:595401.
    PubMed         Abstract available
    
    

    
    Int J Genomics

36. DENG Z, Li Y, Shen Y, Zhou M, et al
    Comprehensive Analysis Based on the Cancer-Immunity Cycle Identifies a Novel Immunosuppressive Subtype of Bladder Cancer.
    Int J Genomics. 2026;2026:9720283.
    PubMed         Abstract available
    
    

    
    Int J Urol

37. HATAKEYAMA S, Yamamoto K, Yamamoto H, Yasui T, et al
    Real-World Outcomes After Radical Cystectomy for Muscle-Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database.
    Int J Urol. 2026;33:e70450.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

38. RUSSO P, Foschi N, Lentini N, Bizzarri FP, et al
    Perioperative outcomes following open radical cystectomy in the setting of locally advanced bladder cancer.
    Int Urol Nephrol. 2026 Apr 9. doi: 10.1007/s11255-026-05127.
    PubMed         Abstract available
    
    

    
    J Urol

39. PEDERSEN GL, Mogensen K, Rosthoj S, Erikson MS, et al
    In-Office Laser Coagulation of Ta Bladder Tumor Compared With Transurethral Resection of Bladder Tumor: 12 Months Follow-Up Randomized Clinical Trial.
    J Urol. 2026;215:535-543.
    PubMed         Abstract available
    
    

    
    Lab Med

40. KAYTAZ M, Degirmenci ME, Kucukgergin C, Aydin AF, et al
    Expression of lncRNA-ATB and miR-200c in patients with bladder cancer: a pilot study.
    Lab Med. 2026;57:lmag011.
    PubMed         Abstract available
    
    

    
    Mol Cell Biochem

41. SUN Z, Wang Y, You S, Ji Q, et al
    CREB1-ROC1 axis drives bladder cancer progression under hypoxic conditions.
    Mol Cell Biochem. 2026 Apr 4. doi: 10.1007/s11010-026-05509.
    PubMed        
    
    

    
    Nano Lett

42. XU H, Wu J, Qin J, Li Z, et al
    Dual-Interface Hierarchical Assembly of Asymmetric ICG-Lipid Conjugates Enables Finite J-type Aggregation and Two-Stage NIR-II Fluorescence Enhancement.
    Nano Lett. 2026;26:4296-4305.
    PubMed         Abstract available
    
    

    
    Nat Commun

43. MULLER DC, Murtha AJ, Bacon JVW, Stephenson M, et al
    Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.
    Nat Commun. 2026;17:3263.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

44. CHILD F, Lunj S, Gough J, Humphries MJ, et al
    The hypoxic ECM and neutrophils in MIBC immunotherapy resistance.
    Nat Rev Urol. 2026;23:236-255.
    PubMed         Abstract available
    
    

    
    Oncogene

45. XIAO M, Ma Y, Zhang G, Chen G, et al
    SRSF10 promotes cisplatin resistance in bladder cancer via BIN1 Exon 12 retention and ANXA1 activation.
    Oncogene. 2026 Apr 6. doi: 10.1038/s41388-026-03735.
    PubMed         Abstract available
    
    

    
    Oncol Rep

46. YU G, Jia Z, Dou Z
    [Retracted] miR?24?3p regulates bladder cancer cell proliferation, migration, invasion and autophagy by targeting DEDD.
    Oncol Rep. 2026;55:108.
    PubMed         Abstract available
    
    

    
    Oncology

47. OHNO T, Nakajima Y, Yoshikawa Y, Tsujino T, et al
    Hypoxia-Induced microRNAs confer survival advantage in bladder cancer by fine-tuning oncogenic Pathways.
    Oncology. 2026 Apr 7:1-18. doi: 10.1159/000551754.
    PubMed         Abstract available
    
    

    
    Photodiagnosis Photodyn Ther

48. HIRAO K, Sano T, Taniguchi H, Yanishi M, et al
    Risk factors and management of hypotension and nausea during 5-aminolevulinic acid-assisted transurethral resection of bladder tumors under spinal anesthesia.
    Photodiagnosis Photodyn Ther. 2026;58:105365.
    PubMed         Abstract available
    
    
49. SHIGEHISA R, Fukata S, Pustimbara A, Yoshimura R, et al
    Cytology-stratified evaluation of carcinoma in situ detection using 5-aminolevulinic acid-based photodynamic diagnosis.
    Photodiagnosis Photodyn Ther. 2026;58:105431.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

50. YE F, Han X, Li W, Huang L, et al
    Spatial multiomics profiling reveals ZFP36-mediated immunometabolic reprogramming in bladder cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2505125123.
    PubMed         Abstract available
    
    

    
    Sci Rep

51. SANO T, Taoka R, Miki J, Saito R, et al
    Comprehensive analysis of oncological outcomes of radical cystectomy for non-muscle invasive bladder cancer.
    Sci Rep. 2026 Apr 5. doi: 10.1038/s41598-026-46649.
    PubMed        
    
    

    
    Urol Oncol

52. VAROL N, Belder N, Cetin S, Durgut SG, et al
    Repression of Septin9 inhibits the oncogenic phenotype of bladder cancer.
    Urol Oncol. 2026 Apr 7:111097. doi: 10.1016/j.urolonc.2026.111097.
    PubMed         Abstract available
    
    
53. TAN YG, Fong KY, Abern MR, Lim BJH, et al
    Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis.
    Urol Oncol. 2026 Apr 8:111091. doi: 10.1016/j.urolonc.2026.111091.
    PubMed         Abstract available
    
    
54. BANDO Y, Teishima J, Tobe T, Ueki H, et al
    Adequate Bacillus Calmette-Guerin maintenance therapy improves recurrence-free survival in high-risk non-muscle-invasive bladder cancer: A conditional survival study.
    Urol Oncol. 2026 Apr 2:111087. doi: 10.1016/j.urolonc.2026.111087.
    PubMed         Abstract available
    
    
55. ZAURITO P, Scilipoti P, Longoni M, de Angelis M, et al
    Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort study.
    Urol Oncol. 2026 Apr 2:111089. doi: 10.1016/j.urolonc.2026.111089.
    PubMed         Abstract available
    
    

    
    Urology

56. HINOJOSA-GONZALEZ DE, Salgado-Garza G, Low EL, Saffati-Grunhaus G, et al
    Differences in Postoperative Healthcare Utilization After Robotic and Open Radical Cystectomy: A NSQIP Analysis.
    Urology. 2026;210:71-75.
    PubMed         Abstract available
    
    

    
    Virchows Arch

57. YANG M, Yao Y, Wang K, Qi L, et al
    Clinicopathological characteristics and prognostic significance of HER2 status evaluation in patients with urothelial carcinoma: a retrospective single-center experience in China.
    Virchows Arch. 2026;488:819-830.
    PubMed         Abstract available
    
    

    
    Zhonghua Bing Li Xue Za Zhi

58. ZENG WR, Xu AW, Cheng ZL, Yong JJ, et al
    [Clear cell adenocarcinoma of the urinary tract: a clinicopathological analysis of nine cases].
    Zhonghua Bing Li Xue Za Zhi. 2026;55:326-332.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum